Female sex is associated with improved survival after perioperative immunotherapy in resectable non-small cell lung cancer Authors: Vikram Krishna, Claire Perez, Kellie Knabe, Bryan Navarro, Raffaele Rocco, Andrew R. Brownlee, Clark Fuller, Harmik J. Soukiasian, Philicia Moonsamy Published: 2026 ABSTRACT BackgroundThe impact of sex-related immune modulation on treatment outcomes for patients who receive perioperative immunotherapy is unknown. Given that females are underrepresented in clinical trials investigating immunotherapy, we compared overall survival (OS) by sex for resectable stage IB–IIIA non-small cell lung cancer (NSCLC) patients who received immunotherapy.MethodsThe National Cancer Database (NCDB) was used to identify patients diagnosed with stage IB–IIIA NSCLC who underwent surgical resection and received immunotherapy between 2004 and 2023. The primary outcome was OS after strict 1:1 propensity score matching. Secondary measures included 30-day mortality, 90-day mortality, and length of stay (LOS).ResultsAmong 4,733 patients (47% female), baseline demographics were largely similar, including age, comorbidity, socioeconomic factors, and treatment timing. Females were more likely to undergo lobectomy and have adenocarcinoma histology, while males had more squamous tumors and pneumonectomies (P<0.01). OS differed significantly by sex. After matching (n=3,396), females had improved survival, compared to males {5-year OS 64.9% vs. 60.3%; adjusted hazard ratio (aHR) 0.82 [95% confidence interval (CI): 0.72–0.93], P=0.003}. The greatest benefit was observed in females receiving chemotherapy with perioperative immunotherapy [5-year OS 66.9% (95% CI: 63.3–70.4%), log-rank P<0.001]. There were no differences in 30-day mortality or 90-day mortality.ConclusionsIn patients with resectable stage IB–IIIA NSCLC receiving perioperative immunotherapy, female sex was independently associated with improved OS. This study provides further insight into the impact of sexual dimorphism on immunotherapy outcomes and can help clinicians develop personalized treatment plans for female patients. Highlight box Key findings • In a large national cohort of stage IB–IIIA non-small cell lung cancer (NSCLC) patients undergoing perioperative immunotherapy and surgical resection, female sex was independently associated with improved overall survival (OS) after multivariable adjustment. • Female sex was associated with the greatest 5-year OS benefit among patients receiving combined chemo-immunotherapy, compared with male sex. What is known and what is new? • Phase III trials have demonstrated improved outcomes with perioperative immunotherapy; however, females remain underrepresented in these landmark studies. • Our study provides real-world, national-level evidence that female sex was associated with a significant survival advantage following perioperative immunotherapy for resectable NSCLC. What is the implication, and what should change now? • The results support sex-informed perioperative treatment strategies in NSCLC. • Future trials should ensure adequate female sex representation and pre-specified sex-based analyses. • Translational research should further explore sexual dimorphism in tumor immunobiology. • Clinicians should recognize that patients of female sex may also benefit from perioperative chemo-immunotherapy, informing shared decision-making, and trial enrollment. Introduction In patients with resectable non-small cell lung cancer (NSCLC), 30–55% of patients who undergo curative surgery still have recurrence (1). Neoadjuvant chemotherapy has been shown to improve outcomes. However, the absolute improvement in 5-year recurrence-free survival and overall survival (OS) is modest at only 5–6% (2). Recent phase 3 trials have demonstrated that the addition of perioperative immunotherapy, compared to chemotherapy alone, improves survival and increases the rate of pathological complete response without compromising safety (3-5). Despite the clinical benefits that immunotherapy has brought to the treatment of lung cancer, there was still a persistent underrepresentation of females in the study populations of all landmark trials (e.g., 29% in both CheckMate 816 and CheckMate 77T), and the biological basis for potential sex-related differences in treatment response remains incompletely understood (1). Emerging evidence suggests that sex-related differences in tumor biology and immune-regulation, including variations in T-cell function and PD-1/PD-L1 signaling, may influence immunotherapy response (6). Differences in tumor histology, smoking exposure, and the tumor microenvironment between sexes may also influence treatment response and survival (7). Understanding sex-based differences in response and perioperative immunotherapy is critical, as it may help inform personalized treatment strategies and optimize patient selection in the evolving management of NSCLC. The objective of this study was to compare survival by sex for stage IB–IIIA NSCLC patients who received perioperative immunotherapy. We hypothesized that patients of female sex would have improved survival compared to those of male sex following treatment. We present this article in accordance with the STROBE reporting checklist (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1-0398/rc). Methods Data source This study is a retrospective cohort analysis of patients diagnosed with stage IB-IIIA NSCLC from the National Cancer Database (NCDB) NSCLC Participant User File (PUF) from 2004–2023. The NCDB is a national oncological database co-sponsored by the American College of Surgeons Commission on Cancer and American Cancer Society, collecting data on about 70% of all newly diagnosed invasive cancers in the United States annually (8,9). The data for this study come from a deidentified NCDB file. The study was conducted in accordance with the Declaration of Helsinki and its subsequent amendments. Study design Using a 2023 NCDB PUF, all patients with a confirmed diagnosis of stage IB–IIIA NSCLC who underwent perioperative immunotherapy and surgical resection were included in the study. To limit confounding variables, patients with prior malignancy, those who underwent palliative surgery, had neuroendocrine/missing histology, or lacked survival data were excluded (Figure 1). Sex was defined as biological sex as recorded by the NCDB variable “Sex”. Immunotherapy use was defined by the variable “Immunotherapy”, which states whether immunotherapy was administered as the first course of therapy, indicating this was administered in the neoadjuvant setting. Histology and topography codes were determined by the International Classification of Diseases for Oncology, Third Edition (ICD-O-3). Clinical and pathological staging were recorded using the American Joint Committee on Cancer (AJCC) 8th edition standards; patients diagnosed between 2010 and 2017, when AJCC 7th edition standards were used, were re-classified to 8th edition standards. The primary outcome was 5-year OS, defined by a time-to-event variable using “Last Vital Status” as the binary outcome variable and “Last Contact, Months from Diagnosis” as the time variable, stratified by sex. Secondary outcomes were 30-day mortality, 90-day mortality, and length of stay (LOS). Study population. NCDB, National Cancer Database; NSCLC, non-small cell lung cancer. Statistical analysis Patients were grouped by sex: male and female. Comparisons of patient characteristics and short-term outcomes between the two groups were done using Wilcoxon rank sum test for continuous variables and bivariate χ2 test for categorical variables. Differences in OS between sex groups were assessed with the Kaplan-Meier method and log-rank test. A Cox proportional hazard model was used to evaluate OS, adjusting for clinically relevant variables including the following: age, insurance, Charlson-Deyo comorbidity index, facility type, race, income, education, surgery type, chemotherapy use, radiation use, histology, nodal stage, and pathological stage. Next, propensity score matching was used to create cohorts comparing OS by sex using the following covariates: age, insurance, Charlson-Deyo comorbidity index, facility, race, median income, education, surgery type, chemotherapy use, radiation use, histology, nodal stage, and pathological stage. These variables were chosen based on clinical relevance. In the male-female matched cohort, 1:1 nearest-neighbor matching without replacement using a caliper width of 0.05 was used to find the most appropriately matched groups. Absolute standardized differences were used to assess the match balance. Baseline characteristics were assessed using Wilcoxon rank sum test for continuous variables and bivariate χ2 test for categorical variables. Differences in OS between matched groups were assessed using the Kaplan-Meier method with log-rank test and the Cox proportional hazard model using the same covariates as above. As the NCDB began collecting smoking status in 2023 (10), an additional multivariable Cox regression was performed with “Tobacco Use Smoking Status” included as a covariate. The proportional hazards assumption was assessed using Schoenfeld residuals and was not violated. Furthermore, a sub-analysis evaluated OS according to receipt of perioperative immunotherapy and/or chemotherapy stratified by sex using the Kaplan-Meier method with the log-rank test. Analyses were performed using complete-case data, and observations missing any variables for a given model were excluded. A P value <0.05 was considered statistically significant for all analyses. All statistical analyses were performed using STATA 19.5 (StataCorp, College Station, TX, USA). Results A total of 4,733 patients undergoing perioperative immunotherapy and surgical resection were included: 2,507 male (53.0%) and 2,226 female (47.0%). Baseline demographics and clinical characteristics are listed in Table 1. The median age was 66 years [interquartile range (IQR), 60–72 years] among males and 65 years (IQR, 60–72 years) among females (P=0.37). Insurance differed slightly between the two groups, but Medicare was the most common coverage (males: 53.0% vs. females: 53.6%). Charlson-Deyo score >3 was more prevalent in males (7.3% vs. 5.1%, P=0.02). Both male and female cohorts were similar in terms of income, education, and facility type. Females were more likely to undergo lobectomy (81.2% vs. 75.6%, P<0.01), and males were more likely to undergo pneumonectomy (7.6% vs. 4.1%, P<0.01). Median distance to treating facility was also similar [males: 14.5 (IQR, 6.2–31.5) vs. female: 13.7 (IQR, 5.8–32.4) miles, P=0.36]. Days to immunotherapy [123 (IQR, 57–194) vs. 127 (IQR, 57–202) days, P=0.19] and days to chemotherapy [71 (IQR, 43–109) vs. 74 (IQR, 45–111) days, P=0.08] were similar between the two groups. There were no differences in the rate of chemotherapy use, radiation use, or median LOS in both groups. Table 1Baseline, tumor, and pathological characteristics for patients with NSCLC undergoing perioperative immunotherapy and surgical resection (n=4,733)VariableCategoryMale (n=2,507)Female (n=2,226)P valueAge (years)–66 [60–72]65 [60–72]0.37InsuranceMedicaid205 (8.2)190 (8.5)<0.001Medicare1,329 (53.0)1,193 (53.6)Other/unknown99 (4.0)42 (1.9)Private826 (32.9)778 (34.9)Uninsured48 (1.9)23 (1.0)Smoking status (n=1,381)Ever-smoker682 (91.9)550 (86.1)<0.001Never-smoker60 (8.1)89 (13.9)Charlson-Deyo score01,448 (57.8)1,333 (59.9)0.021645 (25.7)573 (25.7)2230 (9.2)206 (9.3)≥3184 (7.3)114 (5.1)Facility typeAcademic/research1,130 (45.5)960 (43.5)0.40Community cancer program105 (4.2)96 (4.3)Comprehensive community760 (30.6)724 (32.8)Integrated network490 (19.7)429 (19.4)Race/ethnicityHispanic/Latino112 (4.5)107 (4.8)0.03Non-Hispanic Black219 (8.7)219 (9.8)Non-Hispanic White2,026 (80.8)1,807 (81.2)Other/unknown150 (6.0)93 (4.2)Income quartile (n=3,917)1st quartile350 (16.7)303 (16.7)0.802nd quartile478 (22.8)395 (21.8)3rd quartile490 (23.3)416 (22.9)4th quartile783 (37.3)702 (38.7)Education quartile (n=3,922)1st quartile454 (21.6)348 (19.1)0.182nd quartile588 (28.0)547 (30.1)3rd quartile616 (29.3)521 (28.7)4th quartile446 (21.2)402 (22.1)Surgery typeLobectomy1,896 (75.6)1,805 (81.2)<0.001Other surgery203 (8.1)124 (5.6)Pneumonectomy190 (7.6)91 (4.1)Segmentectomy30 (1.2)37 (1.7)Wedge188 (7.5)168 (7.6)Chemotherapy–2,247 (89.8)2,003 (90.1)0.74Radiation–695 (28.0)589 (26.8)0.34Days to immunotherapy–123 [57–194]127 [57–202]0.19Days to chemotherapy–71 [43–109]74 [45–111]0.08Distance to facility (miles)–14.5 [6.2–31.5]13.7 [5.8–32.4]0.36Hospital stay (days)–28 [4–38]28 [7–38]0.67Year of diagnosis–2021 [2019–2022]2021 [2019–2022]0.61Tumor size (mm)–43.5 [30–59]41 [25–58]0.17HistologyAdenocarcinoma1,028 (41.0)1,209 (54.3)<0.001Squamous cell1,085 (43.3)590 (26.5)Large cell52 (2.1)39 (1.8)Adenosquamous/mixed48 (1.9)39 (1.8)Other294 (11.7)349 (15.7)Tumor gradeWell differentiated73 (2.9)81 (3.6)<0.001Moderately differentiated489 (19.5)340 (15.3)Poorly differentiated511 (20.4)501 (22.5)Undifferentiated21 (0.8)8 (0.4)Unknown/other1,413 (56.4)1,296 (58.2)Pathologic stageI306 (12.2)317 (14.2)0.45II699 (27.9)684 (30.7)III831 (33.2)745 (33.5)IV103 (4.1)86 (3.9)OC3 (0.1)2 (0.1)Unknown565 (22.5)392 (17.6)Nodal stageN01,568 (62.6)1,357 (61.0)0.37N1528 (21.1)490 (22.0)N2390 (15.6)359 (16.1)N33 (0.1)1 (0.05)NX18 (0.7)16 (0.7)Tumor locationUpper lobe1,398 (55.8)1,234 (55.4)<0.001Lower lobe779 (31.1)746 (33.5)Main bronchus105 (4.2)37 (1.7)Middle lobe88 (3.5)104 (4.7)Overlapping76 (3.0)49 (2.2)Lung, not specified61 (2.4)56 (2.5)R0 resection–2,030 (87.3)1,904 (89.9)0.00830-day mortality–16 (0.7)9 (0.4)0.5090-day mortality–37 (1.6)26 (1.2)0.55Values are expressed as median [interquartile range] or n (%). N, node; NSCLC, non-small cell lung cancer; OC, occult carcinoma. Baseline, tumor, and pathological characteristics for patients with NSCLC undergoing perioperative immunotherapy and surgical resection (n=4,733) Values are expressed as median [interquartile range] or n (%). N, node; NSCLC, non-small cell lung cancer; OC, occult carcinoma. Furthermore, males were more likely to have main bronchus tumors (4.2% vs. 1.7%), while females were more likely to have middle lobe (4.7% vs. 3.5%) and lower lobe (33.5% vs. 31.1%) tumors (P<0.001). Adenocarcinoma histology was more common in females (54.3% vs. 41.0%), and squamous cell carcinoma was predominant in males (43.3% vs. 26.5%, P<0.001). Females had higher rates of poorly differentiated tumors (22.5% vs. 20.4%, P<0.001). Nodal stage and pathological stage were similar between both groups. Females had higher rates of R0 resection (89.9% vs. 87.3%, P<0.01). There were no differences in 30-day (male: 0.7% vs. female: 0.4%, P=0.50) or 90-day (1.6% vs. 1.2%, P=0.55) mortality. Survival analysis The median follow-up for the entire cohort was 34.5 months [95% confidence interval (CI): 33.8–35.3]. OS differed significantly by sex, with females demonstrating superior survival compared to males (log-rank <0.001, Figure 2). On multivariable Cox proportional hazards analysis, female sex was independently associated with improved OS compared to males [adjusted hazard ratio (aHR) 0.78 (95% CI: 0.68–0.88), P<0.001, Table S1]. Other predictors of worse survival included age [aHR 1.03 (95% CI: 1.02–1.03), P<0.001], care outside of an academic/research program [community cancer program: aHR 1.38 (95% CI: 1.04–1.84), P=0.03; comprehensive community center: aHR 1.25 (95% CI: 1.09–1.45), P<0.002; integrated cancer network aHR 1.24 (95% CI: 1.05–1.47), P=0.01], wedge resection [aHR 1.73 (95% CI: 1.42–2.10), P<0.001], pneumonectomy [aHR 1.78 (95% CI: 1.41–2.25), P<0.001], radiation use [aHR 1.33 (95% CI: 1.16–1.54), P<0.001] and higher pathological stage (stage II–IV, P<0.05). Chemotherapy use was associated with improved survival [aHR 0.70 (95% CI: 0.59–0.84), P<0.001]. Overall survival after perioperative immunotherapy for the unmatched cohort. Five-year survival was stratified by sex. aHR, adjusted hazard ratio; CI, confidence interval. Propensity score-matched analysis A total of 3,396 patients were included in the male-female 1:1 matched cohort. The cohort was well balanced in age, race, Charlson-Deyo score, income, education, and facility type (Table 2); all absolute standardized differences were less than 5% (Table S2). Furthermore, there were no significant differences in nodal stage, pathological stage, tumor size, or rates of R0 resection (Table 2). In terms of short-term outcomes, there were no differences in 30-day mortality or 90-day mortality. Table 2Baseline, tumor, and pathological characteristics for patients with NSCLC undergoing perioperative immunotherapy and surgical resection in matched cohort (n=3,396)VariableCategoryMale (n=1,698)Female (n=1,698)P valueAge (years)–66 [60–72]65 [60–72]0.39InsuranceMedicaid130 (7.7)138 (8.1)0.001Medicare894 (52.7)906 (53.4)Other/unknown73 (4.3)34 (2.0)Private569 (33.5)601 (35.4)Uninsured32 (1.9)19 (1.1)Smoking status (n=976)Never-smoker41 (8.1)69 (14.7)0.001Ever-smoker467 (91.9)399 (85.3)Charlson-Deyo score01,024 (60.3)994 (58.5)0.101432 (25.4)452 (26.6)2136 (8.0)167 (9.8)≥3106 (6.2)85 (5.0)Facility typeAcademic/research770 (45.4)768 (45.3)0.52Community cancer program66 (3.9)77 (4.5)Comprehensive community523 (30.8)541 (31.9)Integrated network339 (20.0)312 (18.4)Race/ethnicityHispanic/Latino84 (4.9)63 (3.7)0.10Non-Hispanic Black156 (9.2)157 (9.2)Non-Hispanic White1,361 (80.2)1,402 (82.6)Unknown/other97 (5.7)76 (4.5)Income quartile1st quartile264 (15.5)288 (17.0)0.732nd quartile385 (22.7)378 (22.3)3rd quartile401 (23.6)389 (22.9)4th quartile648 (38.2)643 (37.9)Education quartile1st quartile347 (20.4)328 (19.3)0.342nd quartile474 (27.9)521 (30.7)3rd quartile500 (29.4)491 (28.9)4th quartile377 (22.2)358 (21.1)Surgery typeLobectomy1,339 (78.8)1,377 (81.1)0.001Other surgery109 (6.4)92 (5.4)Pneumonectomy117 (6.9)67 (3.9)Segmentectomy20 (1.2)29 (1.7)Wedge113 (6.7)133 (7.8)Chemotherapy–1,526 (89.9)1,527 (89.9)0.96Radiation–460 (27.1)466 (27.4)0.82Days to immunotherapy–122 [57–197]130 [57–202]0.31Days to chemotherapy–74 [43–111]75 [46–111]0.23Distance to facility (miles)–14 [6.1–30.7]13.9 [5.8–32.2]0.82Hospital stay (days)–27 [6–35]27 [8–35]0.48Year of diagnosis–2021 [2019–2022]2021 [2019–2022]0.36Tumor size (mm)–40 [30–57]41 [25–57]0.74HistologyAdenocarcinoma719 (42.3)918 (54.1)<0.001Squamous cell707 (41.6)459 (27.0)Large cell36 (2.1)31 (1.8)Adenosquamous/mixed36 (2.1)28 (1.6)Other200 (11.8)262 (15.4)Tumor gradeWell differentiated52 (3.1)57 (3.4)0.004Moderately differentiated327 (19.3)249 (14.7)Poorly differentiated360 (21.2)387 (22.8)Undifferentiated11 (0.6)5 (0.3)Unknown/other948 (55.9)1,000 (58.9)Pathologic stageI245 (14.4)236 (13.9)0.99II516 (30.4)523 (30.8)III583 (34.3)577 (34.0)IV66 (3.9)64 (3.8)Occult carcinoma2 (0.1)2 (0.1)Unknown286 (16.8)296 (17.4)Nodal stageN01,052 (62.0)1,038 (61.1)0.84N1368 (21.7)384 (22.6)N2262 (15.4)265 (15.6)N32 (0.1)1 (0.1)NX14 (0.8)10 (0.6)Tumor locationMain bronchus60 (3.5)30 (1.8)0.002Upper lobe945 (55.6)933 (54.9)Middle lobe60 (3.5)81 (4.8)Lower lobe541 (31.9)581 (34.2)Overlapping50 (2.9)32 (1.9)Lung, not specified42 (2.5)41 (2.4)R0 resection–1,401 (87.7)1,447 (89.6)0.0930-day mortality–12 (0.7)8 (0.5)0.5790-day mortality–23 (1.4)21 (1.3)0.92Values are expressed as median [interquartile range] or n (%). N, node; NSCLC, non-small cell lung cancer. Baseline, tumor, and pathological characteristics for patients with NSCLC undergoing perioperative immunotherapy and surgical resection in matched cohort (n=3,396) Values are expressed as median [interquartile range] or n (%). N, node; NSCLC, non-small cell lung cancer. Survival outcomes for patients in the propensity score-matched cohorts of male-female patients are shown in Figure 3. The 5-year OS for female patients was 64.9% (95% CI: 61.5–68.1%) and 60.3% (95% CI: 56.8–63.6%) for males (log-rank P<0.001, Figure 3). On multivariable Cox regression, female sex remained independently associated with improved survival [aHR 0.82 (95% CI: 0.72–0.93), P=0.003, Table 3]. After adjusting for smoking status, female sex continued to have better OS [aHR 0.64 (0.43–0.95), P=0.03, Table S3]. Furthermore, on sub-analysis, female patients who received chemotherapy in addition to perioperative immunotherapy demonstrated the greatest 5-year OS benefit [66.9% (95% CI: 63.3–70.4%), log rank P<0.001, Figure 4] compared with male patients receiving the same therapy after matched analysis. Overall survival after perioperative immunotherapy for the matched cohort. Five-year survival was stratified by sex. aHR, adjusted hazard ratio; CI, confidence interval. Table 3Multivariable Cox regression for patients with NSCLC undergoing perioperative immunotherapy and surgical resection in matched cohort (n=3,396)VariableCategoryHazard ratio (95% CI)P valueSexFemale0.82 (0.72–0.93)0.003Age1.03 (1.02–1.04)<0.001InsuranceUninsuredReferenceMedicaid0.72 (0.40–1.29)0.28Medicare0.72 (0.42–1.23)0.23Other/unknown0.57 (0.30–1.08)0.09Private0.70 (0.41–1.19)0.18Charlson-Deyo score0Reference10.97 (0.83–1.13)0.7121.09 (0.87–1.37)0.463+1.09 (0.82–1.44)0.57Facility typeAcademic/researchReferenceCommunity cancer program1.56 (1.15–2.11)0.004Comprehensive community1.23 (1.05–1.44)0.009Integrated network1.27 (1.06–1.51)0.01Race/ethnicityWhiteReferenceHispanic/Latino0.93 (0.65–1.32)0.67Non-Hispanic Black0.92 (0.71–1.18)0.52Unknown/other0.93 (0.67–1.30)0.67Median income quartile1stReference2nd1.11 (0.89–1.39)0.353rd1.15 (0.91–1.46)0.254th0.84 (0.65–1.08)0.18Education quartile4th (highest)Reference1st0.79 (0.62–1.02)0.072nd0.77 (0.62–0.96)0.023rd0.85 (0.70–1.03)0.1Surgery typeLobectomyReferenceOther surgery2.17 (1.65–2.86)<0.001Pneumonectomy1.64 (1.26–2.14)<0.001Segmentectomy1.29 (0.78–2.13)0.33Wedge1.81 (1.47–2.23)<0.001Chemotherapy received0.68 (0.56–0.83)<0.001Radiation received1.37 (1.17–1.59)<0.001HistologyAdenocarcinomaReferenceSquamous1.08 (0.93–1.26)0.32Large cell1.86 (1.30–2.67)0.001Adenosquamous/mixed1.55 (1.02–2.35)0.04Other0.90 (0.72–1.12)0.36N stageN0ReferenceN11.19 (1.02–1.40)0.03N20.97 (0.81–1.17)0.77N31.28 (0.31–5.26)0.73NX1.52 (0.82–2.80)0.18Final stageStage IReferenceStage II1.19 (0.92–1.53)0.19Stage III1.98 (1.55–2.52)<0.001Stage IV3.04 (2.19–4.22)<0.001CI, confidence interval; N, node; NSCLC, non-small cell lung cancer. Multivariable Cox regression for patients with NSCLC undergoing perioperative immunotherapy and surgical resection in matched cohort (n=3,396) CI, confidence interval; N, node; NSCLC, non-small cell lung cancer. Overall 5-year survival by receipt of therapy. Five-year survival analysis was stratified by sex and receipt of chemotherapy with or without immunotherapy. Chemo, chemotherapy; IO, immunotherapy. Discussion In a large national analysis, female sex was associated with significantly improved OS after perioperative immunotherapy and surgical resection for NSCLC, even after strict propensity score matching and adjusting for smoking status. Furthermore, females receiving chemoimmunotherapy experienced the greatest survival benefit compared to males. Although the absolute difference in 5-year OS is modest, the finding was consistent across multiple adjusted and propensity-matched analyses. Given the increasing adoption of perioperative immunotherapy in NSCLC, small survival differences can translate to a meaningful impact. The results support the consideration of sex as a biological factor in perioperative treatment selection and clinical trial design. Although insurance and education did not have major significant differences, they were included as important socioeconomic confounders given their known influence on access to care and treatment utilization. Our findings are consistent with prior meta-analyses demonstrating similar sex-based differences in OS among patients after immunotherapy use (6,11). In addition, sex-related benefits have been seen in breast and endometrial cancer treated with chemoimmunotherapy (12-14). Sexual dimorphism in the immune response likely contributes to these differences. Females exhibit differences in T-cell regulation, PD-1/PD-L1 signaling, and X-chromosome-linked epigenetic modulation that influence differences in response to immunotherapy (15-18). In females, the presence of two X chromosomes leads to variations in innate and adaptive immune responses due to gene inactivation, including upregulation of TLR7 and helper T-cells, which may influence the tumor microenvironment. Furthermore, estrogen plays a role in PD-L1 expression upregulation, which affects anti-tumor immunity. In males, downregulation and loss of function of Y-linked genes are associated with increased cancer risk (19,20). Sexual dimorphism exists in NSCLC as well. Transcriptomic analyses of over 2,500 early-stage NSCLC tumors showed that the female tumor microenvironment had a significant increase in T-cell dysfunction, more inhibitory immune checkpoint expression, and more immune-suppressive cells compared to males (21). Furthermore, the upregulation of estrogen receptor α has been associated with improved response to PD-L1 checkpoint inhibitors in NSCLC (22). In untreated advanced NSCLC, female patients treated with a first-line PD-1 inhibitor along with chemotherapy had the greatest survival benefit compared to males (23); however, females only made up 25% of the cohort in the study. While females are traditionally under-represented in clinical trials, especially for NSCLC (24,25), our study used a contemporary large national cohort to provide insight into the survival benefit of perioperative immunotherapy for females. These findings may help inform shared decision-making for female patients, particularly when considering perioperative systemic therapy strategies in patients with resectable NSCLC. Our study has some limitations. In addition to the retrospective design, the NCDB does not provide details on the specific immunotherapy agents or chemotherapy regimens, so we could not account for the heterogeneity of immunotherapy courses patients may have received. Furthermore, the NCDB does not capture molecular tumor characteristics, such as driver mutations or PD-L1 expression. These factors may influence treatment response and survival outcomes and represent potential sources of confounding, which could account for the observed survival differences. Although a comorbidity index is provided, there is no data on pulmonary function or performance status. While LOS was similar between both groups, there is no information on perioperative complications. The use of registry-based coding for treatment variables and staging may have led to misclassification bias. The NCDB also does not provide information on recurrence-free survival or details on lymph node sampling. Also, the median follow-up of 34 months limits the ability to observe late survival benefits that may emerge with longer-term follow-up after perioperative immunotherapy. Conclusions Our findings emphasize the need for sex-informed perioperative strategies and the development of personalized treatment plans for females. Future research should focus on prospective validation of these findings through sex-focused clinical trials and translational studies that examine sexual dimorphism in the tumor microenvironment of NSCLC. In patients with NSCLC undergoing perioperative immunotherapy and surgical resection, our study provides real-world evidence that female sex is associated with improved survival, with the greatest benefit in those who receive chemo-immunotherapy. The findings add to the growing literature on the interplay between sexual dimorphism and tumor oncology and offer an opportunity in personalized lung cancer care. Supplementary The article’s supplementary files as Available at https://jtd.amegroups.com/article/view/10.21037/jtd-2026-1-0398/prf